Filing Flows › BioXcel Therapeutics (BTAIQ) › Recalls, complaints & regulation
BioXcel Therapeutics (BTAIQ): clinical trials
BioXcel Therapeutics (BTAIQ) beyond its filings: 1 active clinical trial.
BioXcel Therapeutics' latest quarter
BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year), net loss $14.7M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does BioXcel Therapeutics have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.